TABLE 1.
Characteristics of all patients and those in the AI fit and unfit groups
| Overall | AI fit | AI unfit | p value | |
|---|---|---|---|---|
| (N = 450) | (N = 337) | (N = 113) | ||
| Age, years | 0.019 | |||
| Median | 71 | 72 | 70 | |
| Range | 31–92 | 34–90 | 31–92 | |
| <75 | 314 (69.8) | 241 (71.5) | 73 (64.6) | 0.193 |
| ≦75 | 136 (30.2) | 96 (28.5) | 40 (35.4) | |
| Sex, n (%) | 0.140 | |||
| Male | 157 (34.9) | 111 (32.9) | 46 (40.7) | |
| Female | 293 (65.1) | 226 (67.1) | 67 (59.3) | |
| Stage, n (%) | 0.017 | |||
| Relapse after surgery | 126 (28.0) | 90 (26.7) | 36 (31.9) | |
| IIIB | 10 (2.2) | 4 (1.2) | 6 (5.3) | |
| IV | 314 (69.8) | 243 (72.1) | 71 (62.8) | |
| ECOG PS, n (%) | 0.026 | |||
| 0 | 128 (28.4) | 104 (30.9) | 24 (21.2) | |
| 1 | 249 (55.3) | 186 (55.2) | 63 (55.8) | |
| 2 | 73 (16.2) | 47 (13.9) | 26 (23.0) | |
| Smoking history, n (%) | 0.743 | |||
| Never | 256 (56.9) | 190 (56.4) | 66 (58.4) | |
| Former/never | 194 (43.1) | 147 (43.6) | 47 (41.6) | |
| Brain metastasis, n (%) | 1.000 | |||
| Yes (asymptomatic) | 140 (31.1) | 105 (31.2) | 35 (31.0) | |
| No | 310 (68.9) | 232 (68.8) | 78 (69.0) | |
| EGFR subtype, n (%) | 0.514 | |||
| L858R | 206 (45.8) | 151 (44.8) | 55 (48.7) | |
| 19 del | 244 (54.2) | 186 (55.2) | 58 (51.3) | |
| EGFR‐TKI, n (%) | 0.127 | |||
| Gefitinib | 273 (60.7) | 200 (59.3) | 73 (64.6) | |
| Erlotinib | 85 (18.9) | 59 (17.5) | 26 (23.0) | |
| Afatinib | 31 (6.9) | 26 (7.7) | 5 (4.4) | |
| Osimertinib | 61 (13.6) | 52 (15.4) | 9 (8.0) |
Abbreviations: 19 del, exon 19 deletion; AI, angiogenesis inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.